Health Law Alliance, under Anthony Mahajan's guidance, reports the successful acceptance of a self-disclosure for Delmar Pharmacy by OIG following a PBM audit identifying Humira dispensing discrepancies. The pharmacy's collaborative decision to disclose limits liability to $218,129.26, emphasizing Health Law Alliance's expertise in PBM audit defense and OIG self-disclosures.

Health Law Alliance is pleased to announce that a self-disclosure filed under Anthony Mahajan’s oversight on behalf of a pharmacy that allegedly dispensed Humira improperly was recently accepted by OIG. As we have noted, OIG self-disclosures may be an effective solution to PBM audit risk.

humira self-disclosure
Humira Pen

OIG’s Self-Disclosure Protocol

The U.S. Department of Health and Human Services, Office of the Inspector General (OIG), encourages providers to voluntarily report self-discovered evidence of potential fraud through the Health Care Fraud Self-Disclosure Protocol.

As we have written about in detail, a discrepant PBM audit may permit providers to learn about and resolve potential liabilities to government healthcare programs through the OIG self-disclosure process.

In short, self-disclosure often presents an excellent opportunity for providers to limit their exposure under administrative, civil, and maybe even criminal law, but the determination whether to make such a voluntary disclosure is extremely complex and must be carefully vetted by experienced healthcare defense attorneys.

The Pharmacy’s Self-Disclosure

In this case, following a PBM audit that identified discrepancies, our attorneys worked closely with the pharmacy to determine whether a self-disclosure was advisable.

The analysis is highly dependent on the specific facts of each case, and a collaborative decision was made that a self-disclosure would be the most effective manner in which to resolve potential liabilities under the False Claims Act and Civil Monetary Penalties law.

Accordingly, following a submission made pursuant to the Self-Disclosure Protocol, Delmar Pharmacy agreed to pay $218,129.26 for allegedly submitting claims to Medicare for Humira for a patient that was delivered by Delmar Pharmacy but not dispensed by the pharmacy.

HLA Specializes in PBM Audit Defense and OIG Self-Disclosures

PBM audits often target high-reimbursing products, such as Humira, and the cost of such products means that a provider’s liability can be extremely high if there are errors. OIG’s acceptance of the self-disclosure, however, effectively limits the pharmacy’s liability for the claims at issue.

In short, PBM audits may identify potential areas in which providers can use OIG’s Self-Disclosure Protocol to limit their exposure on government claims.

At Health Law Alliance, our experienced healthcare defense attorneys are specialists in all relevant self-disclosure protocols and procedures. Indeed, our attorneys possess the background and experience necessary to guide clients through these complex decisions and assist with each step of the self-disclosure process. Contact us today for a free consultation.

Frequently Asked Questions

Semaglutide Compliance Program: A Must Have

The semaglutide industry is relatively new, and significant regulatory enforcement typically lags by at least two years. Accordingly, all participants involved in the semaglutide supply chain should implement well-designed compliance programs now to reduce the risk and severity of future regulatory action.


Federal Prosecutors Focus on Ozempic Violations

Intense semaglutide demand has now drawn the attention of regulators beyond the Food & Drug Administration (FDA) and state boards. Last month, a woman was charged by federal prosecutors with violations of criminal law related to misbranded and adulterated weight loss drugs. This prosecution marks the first of many to come.


Express Scripts FWA Investigative Alert: Crackdown on CoverMyMeds Provider Accounts

Express Scripts is targeting prior authorization Fraud, Waste & Abuse involving the use of CoverMyMeds provider accounts by pharmacies. Pharmacies and physicians beware.


Corporate Advice: Asset Deals – Advantages & Disadvantages

In the final Part Three of a three-part series on corporate transactions, we describe important considerations around structuring the sale of a business as an "asset" sale.